Navigation Links
Penn receives prestigious national award for breakthrough in gene therapy
Date:4/19/2013

PHILADELPHIA A gene therapy study focused on finding a cure for a rare congenital blinding disease has been recognized as one of the ten most outstanding clinical research projects of the year by the Clinical Research Forum (CRF). The study, led by Jean Bennett, MD, Phd, F.M. Kirby professor of Ophthalmology at the University of Pennsylvania School of Medicine, and carried out in collaboration with Penn Medicine's Albert M. Maguire, MD, and Katherine A. High, MD at The Children's Hospital of Philadelphia (CHOP), has been presented with the Distinguished Clinical Research Achievement Award, the second highest given in the CRF's Annual Top 10 Clinical Research Achievement Awards. CRF award winners are cited as the most compelling examples of scientific innovation that results from the nation's investment in clinical research that can benefit human health and welfare.

The results of the most recent phase of the study for Leber's Congenital Amaurosis (LCA) at CHOP have led to the first Phase 3 gene therapy study in the United States and the first Phase 3 gene therapy study in the world for a non-lethal disorder. The team of researchers hopes that the studies could lead to the first approved gene therapy product in the United States.

"The data from our study has already been used to develop additional clinical trials for other blinding diseases," said Bennett. "There are two things that I think are really going to be important from this work: one, that we'll move forward with this particular disease and get approval for the drug that we've been developing, and two, that this could ultimately lead to approved treatments for other currently untreatable conditions."

Published in 2012, the winning studies are the latest in a long tradition of notable health advances that have occurred through clinical research such as eliminating polio, reducing the mortality of AIDS, and improving cancer survival rates that were propelled by combined investment in basic science and clinical research.

"These patients, once rendered blind by LCA, have had their lives transformed and their vision restored by this team's efforts to further gene therapy research," said Joan O'Brien, MD, chair of the department of Ophthalmology at the Scheie Eye Institute at Penn Medicine. "The groundbreaking work sets the stage for the treatment of numerous other blinding conditions, but is also a shining example of what scientists with NIH resources can accomplish for the betterment of humanity."


'/>"/>

Contact: Katie Delach
katie.delach@uphs.upenn.edu
215-349-5964
University of Pennsylvania School of Medicine
Source:Eurekalert

Related biology news :

1. Peihua Jiang receives Ajinomoto Award for Young Investigators in Gustation from AChemS
2. Forsyth Institute receives $4.1 million grant for new center
3. Einstein receives $12 million grant to develop device for preventing HIV infection
4. Wayne State vision restoration technology receives Notice of Allowance for US patent app
5. BU researcher receives highest honor from the National Birth Defects Prevention Network
6. Geneticist Svante Pääbo receives the $500,000 Gruber Genetics Prize
7. Artificial retina receives FDA approval
8. NTU Provost receives prestigious Imperial College fellowship joining the ranks of top UK scientists
9. Xenon Receives a Milestone Payment for Marketing Approval of Glybera in Europe
10. Brainwave "Balancing" Research Receives $1 Million Grant From The Susanne Marcus Collins Foundation, Inc.
11. Celladon Corporation Receives Notice of Allowance from United States Patent and Trademark Office
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/18/2016)... -- --> --> Competitive ... Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance & Detection Systems ... security market and the continuing migration crisis in the ... has led visiongain to publish this unique report, which ... defence & security companies in the border security market ...
(Date:3/14/2016)... 2016 http://www.apimages.com ) - ... - Renvoi : image disponible via AP Images ... --> DERMALOG, le leader de ... lecteurs d,empreintes digitales pour l,enregistrement des réfugiés en ... pour produire des cartes d,identité aux réfugiés. DERMALOG ...
(Date:3/9/2016)... NEW YORK , March 9, 2016 ... current and future states of the RNA Sequencing (RNA ... in segments such as instruments, tools and reagents, data ... Analyze various segments of the RNA-Sequencing market such ... RNA-Sequencing services Identify the main factors affecting each segment ...
Breaking Biology News(10 mins):
(Date:5/5/2016)... , May 5, 2016  Why are two uber-successful ... Lorna Weir launching a new venture—yet going ... they believe that truly helping clients raise the value ... now demands a different type of collaboration. ... the pharmaceutical, biotechnology and medical device sectors. Elevate specializes ...
(Date:5/4/2016)... , May 4, 2016  Bayer today announced ... compound Stivarga ® (regorafenib) tablets for the ... has met its primary endpoint of a statistically ... RESORCE, evaluated the efficacy and safety of regorafenib ... after treatment with sorafenib. The safety and tolerability ...
(Date:5/3/2016)... India , May 3, 2016 /PRNewswire/ ... (DNA Chip (Genomics, Drug Discovery, Gene Expression) ... End user (Academics Institutes, Diagnostics Centers), Fabrication ... published by MarketsandMarkets, the market is expected ... from USD 7.63 Billion in 2015, growing ...
(Date:5/3/2016)... ... May 03, 2016 , ... Kerafast Inc., developers ... from laboratories across the globe, today announced the availability of a Zika virus ... research toward treatment and prevention measures for the Zika virus, the virus’s geographical ...
Breaking Biology Technology: